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Cockayne syndrome (CS) is a severe neurodevelop-
mental disorder characterized by growth abnor-
malities, premature aging, and photosensitivity.
Mutation of Cockayne syndrome B (CSB) affects
neuronal gene expression and differentiation, so
we attempted to bypass its function by expressing
downstream target genes. Intriguingly, ectopic
expression of Synaptotagmin 9 (SYT9), a key
component of the machinery controlling neurotro-
phin release, bypasses the need for CSB in neurito-
genesis. Importantly, brain-derived neurotrophic
factor (BDNF), a neurotrophin implicated in neuronal
differentiation and synaptic modulation, and phar-
macological mimics such as 7,8-dihydroxyflavone
and amitriptyline can compensate for CSB defi-
ciency in cell models of neuronal differentiation as
well. SYT9 and BDNF are downregulated in CS pa-
tient brain tissue, further indicating that sub-optimal
neurotrophin signaling underlies neurological de-
fects in CS. In addition to shedding light on cellular
mechanisms underlying CS and pointing to future
avenues for pharmacological intervention, these
data suggest an important role for SYT9 in neuronal
differentiation.INTRODUCTION
Cockayne syndrome (CS) is a hereditary, multisystem disease,
characterized by neurological and developmental impairment
as well as sun sensitivity and progeroid-like features (Brooks,
2013). Despite the accumulating knowledge on the role of the
main causative gene,Cockayne syndrome B (CSB), in the control
of various biological processes, an understanding of its role in2554 Cell Reports 14, 2554–2561, March 22, 2016 ª2016 The AuthorCS has been missing. Indeed, a lack of effective mechanism-
based therapeutic approaches means that CS is devastating,
with a large number of symptoms related to nervous system
deficiencies and often resulting in death within the first decade
of life.
CSB is a member of the SWI2/SNF2 family of ATP-dependent
chromatin remodeling factors (Troelstra et al., 1992; Citterio
et al., 1998), and its mutation accounts for the vast majority
(80%) of CS cases. Certain mutations in the CS genes can
also give rise to the clinically less severe UV-sensitive syndrome
(UVSS) (reviewed in Spivak, 2005). CSB is a multi-functional
factor. Indeed, it has been implicated not only in transcription-
coupled nucleotide excision repair (TC-NER) and base excision
repair but also in mitochondrial function and regulation of tran-
scription (reviewed in Weidenheim et al., 2009; Brooks, 2013;
Scheibye-Knudsen et al., 2013; Ve´lez-Cruz and Egly, 2013;
Vermeulen and Fousteri, 2013).
Studies of the molecular mechanisms underlying human dis-
ease have often relied on animal models. Intriguingly, while
mice lacking Csb show sun sensitivity, they do not display the
same severe growth retardation, neurologic defects, or high
early mortality that is characteristic of human CS patients (van
der Horst et al., 1997). Thus, the mouse model appears to pro-
vide an excellent model for UVSS, while it is arguably somewhat
less helpful for our understanding of CS. Interestingly, recent
studies in different human cell differentiation systems showed
that a lack of functional CSB represents a barrier to neuronal
cell differentiation (Ciaffardini et al., 2014; Wang et al., 2014).
For example, we reported that direct reprogramming of CS fibro-
blasts to neurons is defective and that little or no differentiation of
neuroblastoma cells to neuron-like cells was observed in the
absence of CSB (Wang et al., 2014). This correlated with gene
expression defects in neuronal gene networks (which were not
observed in the mouse), suggesting that transcription defects,
rather than DNA repair- or mitochondrial defects, underlie the
severe neurologic symptoms of CS (Wang et al., 2014). However,
the mechanism and important downstream implementing fac-
tors remained unknown. Crucially, without knowledge of theses
Figure 1. Ectopic SYT9 Expression Can
Bypass the Requirement for CSB Function
during Differentiation of SH-SY5Y Cells
(A) CSB-depleted SH-SY5Y cells were trans-
duced with lentivirus carrying control, IL2 shRNA,
or SYT9 cDNA. On day 2 after transduction, cells
were induced to differentiate by RA addition. Tuj1
(green) and DAPI (blue) staining was performed on
day 6 after RA treatment. j depicts differentiation in
WT cells for comparison (compare to e and f).
Scale bar, 100 mm.
(B) Differentiation quantitated by Tuj1-positive
cells. Bar graphs represent means ± SD (n > 500
cells per data point).
(C) Differentiation of WT (sh-Ctrl) and SYT9-
depleted (sh-SYT9) cells, as in (A) and (B). Scale
bar, 100 mm. Bar graphs represent means ± SD
(n > 500 cells per data point).factors, mechanism-based therapeutic approaches remain
elusive.
Here, we used different human cell models to comprehen-
sively examine the connection between CSB-dependent gene
expression and neurogenesis. This led to the discovery that
brain-derived neurotrophic factor (BDNF), or its pharmacologic
mimics, can partially bypass the requirement for CSB in neuronal
differentiation. These findings provide an understanding of the
basic mechanisms underlying CS and give hope for future dis-
ease intervention.
RESULTS
We previously showed that reprogramming of CS fibroblasts to
neuron-like cells is defective and that CSB-depleted SH-SY5Y
neuroblastoma cells fail to differentiate. This correlates with de-
fects in transcriptional regulation of relevant neuronal genes. By
examining the transcriptome during differentiation of SH-SY5Y
cells, we identified100 CSB-dependent genes that display sig-
nificant temporal and quantitative changes (Wang et al., 2014).
We surmised that, if gene expression deficiencies are, indeed,
the cause of differentiation defects in CSB-depleted SH-SY5Y
cells, rather than just correlating with them, then it might be
possible to bypass CSB function by artificially altering the
expression of these downstream, CSB-regulated genes. This
approach would also address the relative importance of CSB
in the regulation of gene expression and DNA repair for neuronal
development and survival. In this endeavor, we restricted our
focus to genes whose expression changed in a consistent
manner during neuronal differentiation, temporally and quantita-
tively (i.e., sustained increases or decreases), as such character-
istics could be mimicked by ectopic gene expression or RNAi
knockdown. From a number of candidates (Wang et al., 2014),Cell Reports 14, 2554–2561we chose to further analyze DCN (encod-
ing decorin, a small proteoglycan) and
SYT9 (Synaptotagmin-9), which were up-
regulated, and IL2 (interleukin-2), which
was downregulated, in wild-type (WT)
but not CSB-depleted cells. As a ‘‘con-trol,’’ we also examined KPNA1 (karyopherin alpha-1), which
varied in expression during the time course, showingmodest de-
creases in expression at early time points, and then increased
moderately 9 days after retinoic acid (RA) addition in WT cells,
but not to the same extent in CSB-deficient cells (Wang et al.,
2014) (Figures S1A and S1B).
Ectopic expression of DCN and KPNA1 failed to affect the
differentiation defects caused by CSB depletion (Figure S2A).
Remarkably, however, expressing SYT9 or knocking down
IL2 partially rescued the defects in RA-dependent neurite
outgrowth, as indicated by an increase in cells positive for
Tuj1, a marker of neuron differentiation (Figure 1A). Indeed,
SYT9 re-expression brought differentiation efficiency back to
almost half that observed in WT SH-SY5Y cells (Figure 1B). We
previously reported that CSB is also required for the mainte-
nance of neurites in already differentiated SH-SY5Y cells
(Wang et al., 2014). Interestingly, neurites were stable over a
long time period in cells ectopically expressing SYT9 (or in which
IL2 was knocked down) (Figure S2B), suggesting that the posi-
tive effect was maintained. We also confirmed that SYT9 protein
levels are increased during differentiation of WT SH-SY5Y cells
(Figure S3A). Moreover, RNA polymerase II (RNAPII) and CSB
chromatin immunoprecipitation (ChIP) suggested that the
SYT9 gene might be directly regulated by CSB during the early
stages of differentiation, with CSB occupancy levels at the
gene mirroring gene expression levels (Figures S3B and S3C).
SYT9 is a member of the large synaptotagmin family of vesicle
proteins that control calcium-dependent exocytosis. The spe-
cific function of SYT9 has been the subject of some debate (Xu
et al., 2007; Zhu et al., 2007; Dean et al., 2012), but recent results
indicate that it is associated with dense core vesicle dynamics
and the release of neurotrophic factors and neuropeptides
(Dean et al., 2012). Consistent with an important role for SYT9, March 22, 2016 ª2016 The Authors 2555
Figure 2. Ectopic SYT9 Expression ‘‘Cor-
rects’’ Gene Expression Deficiencies in
CSB-Depleted Cells
(A) Strategy used to identify SYT9-regulated genes
during differentiation in CSB-depleted cells.
(B) Normalized relative expression, shown as
heatmaps, of differentially expressed genes in
CSB-depleted SH-SY5Y cells ectopically ex-
pressing SYT9. Genes with a fold change >1.5
and an adjusted p value < 0.05 relative to control
(Vector) were included, with gene expression inWT
cells, which were previously compared with the
CSB-depleted cells (Wang et al., 2014), shown on
the right at the same time points as reference.
Cream color (‘‘0’’) for any individual gene is the
average across the three relevant samples, and
other values are relative to that.
(C) WT and CSB-depleted SH-SY5Y cells were
treated with RA and BDNF (3.5 nM) as indicated,
and images were taken on day 6 after treat-
ment. Arrowheads denote examples of neurite
outgrowth. Scale bar, 100 mm.in neuronal differentiation of SH-SY5Y cells, we found that short
hairpin RNA (shRNA)-mediated knockdown of SYT9 significantly
reduced RA-induced differentiation in these cells (Figure 1C;
Figure S4A).
The ability to partially bypass CSB’s function by modulating
expression of SYT9 was intriguing. However, given SYT9’s role
as a regulator of secretory granule release, it seemed reasonable
to expect that it was part of the complex signaling pathways acti-
vating the gene expression circuitries that underlie neuritogene-
sis. In this model, ectopic expression of SYT9 compensates for
CSB loss by helping to bring about the gene expression changes
required for differentiation through other means. Supporting the
notion of gene regulatory networks involving SYT9, we note that
IL2 may compensate for CSB inactivation, at least partially, via
SYT9. Indeed, while SYT9 overexpression did not cause a reduc-
tion in IL2 expression (Figure S4B), knockdown of IL2 led to up-
regulation of SYT9 (Figures S4C and S4D).
To directly investigate whether gene regulatory networks
are indeed (re-)activated upon SYT9 expression, we compared
the transcriptome of CSB-depleted SH-SY5Y cells expressing
SYT9 with that of cells carrying only the empty vector, on days 3
and 6 after RA addition (Figure 2A). Genes that were differentially
expressed between these two cell lines were identified (all
affected genes are listed in Table S1), and transcript levels in
this group of genes were depicted next to the previously estab-
lished WT expression levels at the same time points (Figure 2B).
Strikingly, while the gene expression profiles changed markedly
over timeafter RAaddition, thoseofCSB-deficient cells that over-
expressedSYT9were consistentlymore similar to that ofWTcells
than to those of the parental CSB-depleted cells; genes that were
lowly expressed inCSB-depletedcells, compared toWT, typically
became more highly expressed upon SYT9 overexpression (and
vice versa for the relatively highly transcribed genes in CSB-
depleted cells), indicating that SYT9 overexpression partially
‘‘corrected’’ theexpressionofgenesaffectedbyCSB inactivation.
This suggests that CSB and SYT9 both provide important inputs2556 Cell Reports 14, 2554–2561, March 22, 2016 ª2016 The Authorto the same gene regulatory networks, enabling an elevated
SYT9 input to partially compensate for the absence of CSB.
Interestingly, when analyzing the genes whose expression
was most affected by SYT9 expression, we noticed that BDNF
and its receptor, tropomyosin receptor kinase B (TRKB), were
both significantly upregulated upon SYT9 expression (Figures
S5A and S5B). As a master regulator of neuronal survival, differ-
entiation, and synaptic plasticity (Park and Poo, 2013), and a
likely cargo of SYT9-regulated dense core vesicles (Dean
et al., 2012), BDNF appeared an excellent candidate for further
studying differentiation and neuritogenesis in CSB-depleted
cells. In apparent support of this idea, addition of recombinant
human BDNF bypassed the need for CSB, inducing neuritogen-
esis in CSB-depleted SH-SY5Y cells (Figures 2C and 3A). A
similar lack of requirement for CSB during neuronal differentia-
tion when using conditions that involve the addition of both RA
and BDNF (Encinas et al., 2000) has recently been observed
by others (Iyama et al., 2015).
It would be of potential clinical relevance if it were possible to
pharmacologically compensate for the lack of CSB function in
neuronal differentiation and maintenance. Unfortunately, the
therapeutic use of BDNF is limited, due to its poor pharmacoki-
netic profile (Jang et al., 2010). However, small-molecule ago-
nists of TRKB, such as 7,8-dihydroxyflavone (7,8-DHF) and
amitriptyline, can mimic BDNF stimulation, and recent results
suggest that these might be promising therapeutic tools for the
treatment of neurological disease (Jang et al., 2010; Jiang
et al., 2013; Cong et al., 2015; Zhao et al., 2015). To investigate
the possible effect of BDNF mimics in bypassing CSB function,
we treated CSB-depleted SH-SY5Y cells with these agonists.
As controls for specificity, we also used a selective TRKA
agonist, gambogic acid (GA), as well as the TRKB antagonist,
ANA-12. Remarkably, the TRKB agonist-treated cells grew neu-
rites, and the differentiation efficiency was comparable to that of
CSB-deficient cells overexpressing SYT9 (Figure 3; Figure S6A).
In contrast, and as expected, GA and ANA-12 failed to rescues
Figure 3. TrkB Agonists Can Rescue the Differentiation Defects of
CSB Depletion in SH-SY5Y Cells
(A) CSB-depleted SH-SY5Y cells (CSB shRNA [shCSB]) were treated with
BDNF (3.6 nM), amitriptyline (100 nM), or 7,8-DHF (100 nM) and immuno-
stained with Tuj1 antibodies on day 6 after 10 mM RA treatment. Control-
depleted SH-SY5Y cells (shGFP) are shown for comparison. Scale bar,
100 mm.
(B) Quantitation of cells expressing Tuj1. Bars represent means ± SD (n > 500
cells per data point).the defects, with GA causing significant cell death (Figure S6B).
Amitriptyline restored TRKB phosphorylation without affecting
expression levels (Figure S7).
Together, the aforementioned data are consistent with the
idea that CSB inactivation results in the sub-optimal expression
of gene regulatory networks that are activated by BDNF during
differentiation of neuroblastoma cells and that CSB function
can be, at least partially, bypassed by artificially re-activating
these networks, through SYT9, BDNF, or BDNF-mimicking
drugs such as 7,8-DHF and amitriptyline.
Up to this point, the data were generated using neuroblastoma
SH-SY5Y cells, and it could be argued that these are not an ideal
or general model for neuronal differentiation and maintenance in
humans. We note, however, that we previously found SYT9 and
BDNF to be among the most downregulated genes in human
cerebella from CS patients (Wang et al., 2014). To expand on
this finding, we now compared the gene expression profiles of
cerebrum samples from post-mortem CS patients and matched
controls. Gratifyingly, SYT9 and BDNF were among the most
significantly downregulated genes in CS patients also in this
tissue (Table S2), arguing for a general effect of CSB mutation
on the gene regulatory networks encompassing these factors
in human brains.CellTo further expand on the findings in the SH-SY5Y neuroblas-
toma cells, we also used the human neural progenitor stem
cell line, ReNcell VM, which can readily differentiate into the
principal neural cell types, including neurons. Upon infection
with CSB shRNA-containing lentivirus, CSB protein was barely
detectable in these cells (Figure 4A). Tellingly, expression of
SYT9 was dramatically increased during neuronal differentiation
in WT, but not in the CSB-depleted cells (Figure 4B, left panel),
suggesting that, as in SH-SY5Y cells, normal SYT9 gene activa-
tion requires CSB during neuronal differentiation of ReNcell VM.
CSB was also required for the induction of neuronal differentia-
tion marker, MAP2 (Figure 4B, right panel). More importantly,
staining for neurons with Tuj1 antibody was greatly reduced
in CSB-depleted ReNcell VM cells, suggesting that CSB is
required for neuronal differentiation also in this cell line (Fig-
ure 4C; compare panels b and e with panels a and d). However,
as previously observed in SH-SY5Y, treatment with amitriptyline
partially restored differentiation (Figure 4C, c and f). In contrast,
and as expected, the antagonist ANA-12 was unable to rescue
the defects (Figure S8).
Fibroblast-derived, induced pluripotent stem cells (iPSCs)
from patients represent an alternative approach to the study
of neurodevelopment and neurodegenerative disease (Dimos
et al., 2008). Recent data show that, consistent with our previous
results (Wang et al., 2014), iPSCs derived from CS patient cells
are partially defective in neuronal differentiation (Vessoni et al.,
2016). Therefore, to further expand on the finding that CSB
function can be bypassed with TrkB agonists in neuroblastoma
cells and ReNcell VM cells, we derived neurons from CSB pa-
tient-derived iPSCs and cultured these for 1 week in the absence
or presence of TRKB agonists amitriptyline or 7,8-DHF. Gratify-
ingly, an increase in neurite number and arborization in patient-
derived cells by treatment with these small molecules was
observed (Figures 4D–4G), consistent with the notion that
increased TrkB signaling can improve neuronal differentiation
in CS models.
Together, these results indicate that the effect of CSB deple-
tion on gene regulatory networks and neuronal cells is not
restricted to a particular cell type but that it has general validity,
with similar results obtained in three different human cell models.
DISCUSSION
CS isadevastatingdiseasewithhighmortality at a very youngage
and a large number of clinical symptoms related to deficiencies in
neuronal development and maintenance (Brooks, 2013). Manag-
ing or treating the disorder requires better knowledge about the
underlying mechanism. A large number of different possible mo-
lecular causes of CS theories have been proposed (reviewed in
Brooks, 2013). Here, we have added significant evidence to sup-
port the idea that imperfect gene regulation, rather than DNA
repair defects, underlies CS neurologic disease. The finding that
CSB’s function in neuronal differentiation and neuritogenesis
can be, at least partially, bypassed in cell culture is encouraging,
because itpoints tobothadiseasemechanismandpossiblephar-
macological intervention. Crucially, we find that SYT9 and the
secreted cargoesof thedense core vesicles it regulates (including
BDNF) are, indeed, among the most downregulated in cerebellaReports 14, 2554–2561, March 22, 2016 ª2016 The Authors 2557
Figure 4. CSB Function Can Also Be By-
passed in Human Neural Stem Cells ReNcell
VM and CSB iPSC Cells
(A) Western blot analysis of total extracts from
ReNcell VM cells stably transduced with lentivirus
carrying shCSB or control shRNA (shCtrl) for the
indicated times. Note that the CSB-PiggyBac
fusion protein (Bailey et al., 2012) is not affected by
this CSB shRNA.
(B) Gene expression levels over time after serum
withdrawal in WT (shCtrl) and CSB-depleted
ReNcell VM cells (shCSB) assessed by qRT-PCR.
Primers are given in Table S3. A western blot
showing SYT9 levels is also shown.
(C) WT (GFP shRNA), and CSB-depleted ReNcell
VM cells treated with amitriptyline (100 nM) or
DMSO solvent alone (DMSO ctrl) were stained for
Tuj1 (green) and DAPI (blue), 1 or 2 weeks after
serum withdrawal. Scale bar, 100 mm.
(D) CSB iPSC-derived neurons were treated with
amitriptyline (50 nM), 7,8-DHF (50 nM), or vehicle
for 1 week and immunostained with Tuj1 anti-
bodies. Quantitation of the number of neurites per
cell. Bars represent mean ± SEM (n > 500 cells per
data point). ***p < 0.0001.
(E) Same as in (D), but quantitation of neurite length
per neuron. ***p < 0.0001.
(F) Same as in (D), but quantitation of neurite
branches per neurite. ***p < 0.0001.
(G) Representative image of CSB iPSC-derived
neurons treated with vehicle, amitriptyline or
7,8-DHF for 1 week. Arrows indicate regions with
neurite branching in drug-treated cells, rarely
observed in controls. Scale bar, 100 mm.
See also Table S3.and cerebrum fromCSpatients. In general, the concurrent down-
regulation of so many genes involved in regulated exocytosis
is likely to signify disruption of an entire gene regulatory network
encompassing these genes.
Interestingly, work by Crabtree and co-workers has shown
that another chromatin remodeler, BAF, also plays an important
role in neuronal differentiation through an affect on gene regula-
tory networks, and microRNAs in particular (Sun et al., 2013).2558 Cell Reports 14, 2554–2561, March 22, 2016 ª2016 The AuthorsThis led to the discovery that cellular re-
programming and neuronal differentiation
can be induced by the ectopic expression
of such microRNAs (Yoo et al., 2011).
Numerous examples of induced cell
differentiation in culture (cellular reprog-
ramming) have now been described (re-
viewed in Amamoto and Arlotta, 2014).
Induced differentiation in such systems
is invariably brought about by artificially
expressing transcription factor cocktails,
and/or microRNAs; however, to the best
of our knowledge, driving differentiation
via proteins enabling exocytosis has
not previously been reported. Given that
BDNF and its pharmacological mimics,
amitriptyline and 7,8-DHF, can alsocompensate for CSB deficiency, we speculate that increased
expression of SYT9 leads to increased biogenesis, transport to
release sites, and/or exocytosis of dense core vesicles, allowing
augmented neurotrophin release and signaling. This would, in
turn, help compensate for sub-optimal gene expression levels
in CSB-deficient cells, helping to push through the gene expres-
sion changes required to allow differentiation. It is an exciting
possibility that efficient cellular reprogramming might more
generally be achieved via stimulation of dense core vesicle
release, which might drive differentiation in other cell and tissue
systems as well.
While Csb/ mice do not display the severe phenotypes
that might have been expected from the human disease, we
note that Bdnf/ mice have decreased lifespan with nervous
system dysfunction, including ataxia. Although their CNSs
show no gross structural abnormalities, these mice also have
substantially reduced numbers of cranial and spinal sensory
neurons, and myelination defects (Ernfors et al., 1994; Jones
et al., 1994; Cellerino et al., 1997), similar to what is observed
in CS patients.
It is worth mentioning that, even though neuronal differentia-
tion experiments with CSA-deficient cells could not be per-
formed due to inefficient knockdown of CSA, we have previously
reported that the gene expression defects observed in CSB
fibroblasts are also observed in cells from CSA patients (Wang
et al., 2014). Therefore, it seems reasonable to expect that
CSA-deficient cells will show neuronal differentiation defects,
and responses to drugs, that are similar to those of the CSB-defi-
cient cells used here.
Arguably, the most exciting result of this study is the finding
that the defects in neuronal differentiation and neuritogenesis
observed in cells depleted for CSB can be partially bypassed
by the addition of amitriptyline or 7,8-DHF. Amitriptyline is one
of the most widely prescribed prophylactic medications for
severe pediatric migraine (O’Brien et al., 2015). Unfortunately,
its safety profile in CS patients has not been established, but
given the limited treatment options available to these patients,
we suggest that such trials be given high priority.
EXPERIMENTAL PROCEDURES
Cell Lines
SH-SY5Y cells were maintained in DMEM: Ham’s F12 medium (1:1) supple-
mented with 15% fetal bovine serum (FBS) and 1% (v/v) penicillin/strepto-
mycin and maintained in a 37C incubator with 5% CO2. ReNcell VM human
neural stem cells were purchased from EMD Millipore. They were plated
onto laminin (2 mg/ml, L2020, Sigma-Aldrich)-coated cell culture flasks and
maintained in ReNcell NSCmaintenancemedia (SCM005, EMDMillipore) sup-
plemented with 20 mg/ml epidermal growth factor (EGF) and 20 mg/ml basic
fibroblast growth factor (bFGF) (GF144, GF003, EMD Millipore). Cell culture
media were changed every other day until cells were confluent.
Lentiviral Vectors
CSB-KD SH-SY5Y cells were described previously (Wang et al., 2014). The
lentiviral plasmids (pLKO.1) encoding shRNAs against CSB (target sequence:
50-TTATTCCATCTCCTTAACCGC3-0) or GFP (target sequence: 50-GCAAGCT
GACCCTGAAGTTCAT3-0) were from GE Healthcare, Dharmacon. Lentiviral
particles were packaged in HEK293T cells. To transduce the ReNcell VM cells
with the constructs, 50–100 ml viral solution (13 106 transducing units (TU)/ml)
was added to 75%–85% confluent proliferating ReNcell VM cells in six-
well dishes, incubated for 24 hr, and selected with puromycin (1 mg/ml) for
3–5 days.
For the rescue experiments, lentivirus constructs expressing human SYT9
cDNA, human DCN cDNA, human KPNA1 cDNA, and shRNAs against human
IL2 (target sequence: 50-TATTGCTGATTAAGTCCCTGGG-30 ) were purchased
from DharmaconGE. To transduce the CSB-KD SH-SY5Y cells, 50–100 ml viral
solution (1 3 106 TU/ml) were added to 50% confluent cells in six-well dishes
and incubated for 24 hr, and medium was replaced by differentiation medium.
For the ChIP assay, a lentiviral construct expressing human CSB cDNA
was purchased from Applied Biological Materials (ABM) (http://www.Cellabmgood.com). To transduce the WT SH-SY5Y cells, 500 ml viral solution
(1 3 106 TU/ml) was added to 50% confluent cells in 10-cm dishes and
incubated for 24 hr before changing the medium with differentiation
medium.
In Vitro Differentiation
SH-SY5Y cells were plated onto poly-L-lysine (50 mg/ml)-coated plates and
differentiated in the presence of reduced serum (0.5% FBS) and 10 mM RA
as previously described (Wang et al., 2014).
ReNcell VM cells were plated onto laminin (2 mg/ml)-coated six-well plates
and maintained in ReNcell NSC maintenance media supplemented with EGF
(20 mg/ml) and bFGF (20 mg/ml) for 24 hr, and the cell culture medium
was then replaced by differentiation medium and refreshed every 3 days for
1–4 weeks. In some experiments, BDNF (50 ng/ml or 3.6 nM) (Peprotech)
was added with 10 mM RA to CSB-depleted cells.
For TrkB agonist and antagonist treatment in SH-SY5Y and ReNcell VM
cells, 7,8-DHF hydrate, amitriptyline hydrochloride, and ANA-12 were pur-
chased from Sigma-Aldrich and dissolved in DMSO (for 7,8-DHF hydrate) or
H2O (for amitriptyline and ANA-12) to generate 20 mM stock solutions; GA
was dissolved in ethanol to make a 20 mM stock solution. Cells were treated
with various concentrations of the agonists and antagonists as indicated.
Immunofluorescence
Cells were fixed and immunostained as previously described (Wang et al.,
2014). The following primary and secondary antibodies were used: rabbit
anti-Tuj1 monoclonal (1:1,000, MRB-435P, Covance) and Alexa Fluor 488
anti-rabbit (1:1,000, Life Technologies). Coverslips were counterstained with
DAPI and mounted on slides using mounting medium with DAPI (Vector Lab-
oratories). Images were acquired on a Zeiss Axio Imager M1 microscope
equipped with an ORCA-ER camera (Hamamatsu) and controlled by Velocity
5.5.1 software. For cell counts, fluorescent images of the cells were collected
using a 103 objective lens. At least 500 cells per condition and experiment
were analyzed.
Western Blots
Whole-cell lysates were prepared as previously described (Wang et al., 2014).
Primary antibodies were used at the following dilutions: anti-CSB (1:1,000,
A301-345A, Bethyl Laboratories); anti-SYT9 (1:1,000, NBP1-92472, Novus
Biologicals); anti-MAP2 (1:1,000, MAB3418, EMD); anti-Tyrosine Hydroxylase
(1:500, AB152, EMD); anti-a-tubulin (1:10,000, ab15246, Abcam); anti-TrkB
(1:1,000, 4606S, Cell Signaling); and anti-phospho-TrkB Tyr706 (1:500,
C50F3, Cell Signaling).
ChIP-qPCR
ChIP was performed as described elsewhere (Saponaro et al., 2014). Briefly,
cells were cross-linkedwith 1% formaldehyde solution for 15min at room tem-
perature. Cross-linking was quenched by the addition of glycine to a final con-
centration of 125 mM. Samples were sonicated to generate DNA fragments of
less than 500 bp. For immunoprecipitation, 1 mg of GFP antibody (ab290, Ab-
cam) or 2 mg of RNAP II antibody (N-20, Santa Cruz Biotechnology) was added
to the cleared chromatin and incubated overnight at 4C in the presence of
25 ml slurry of protein G-sepharose beads. Immunoprecipitated DNA was
quantified by real-time PCR. Primers sequences used in qPCR are described
in Table S3.
RNA Extraction, qRT-PCR, and DNA Microarray
Total RNAwas prepared as described earlier (Wang et al., 2014). For qRT-PCR,
complementary DNAs from 100 ng of total RNAs were synthesized using the
TaqMan Reverse Transcription Reagents Kit (Life Technologies). Real-time
qPCR was carried out with the iQ-SYBR Green Master Mix (BioRad) using the
CFX96 Real-Time PCR system (BioRad). Gene expression levels were normal-
ized against GAPDHand 18S rRNA levels in each sample, and the fold changes
were calculated by setting the expression levels of each gene in control cells
as 1. Primer sequences are listed in Table S3. We performed RNA isolation
from tissues and DNA microarray as previously described (Wang et al., 2014).
For microarray experiments, double-stranded cDNAs were synthesized
from 10 mg of total RNA using the cDNA synthesis kit according to the RocheReports 14, 2554–2561, March 22, 2016 ª2016 The Authors 2559
user protocol. Up to 1 mg of double-stranded cDNA was labeled with Cy3 and
hybridized on a NimbleGen 12 3 125K Human Expression array, followed by
washing and drying according to the manufacturer’s instructions (NimbleGen,
Roche). Arrays were scanned with a NimbleGen MS200 micro-array scanning
system, and data acquisition was performed with NimbleScan according to
the manufacturer’s protocols.
Neuronal Differentiation of CSB iPSCs
iPSCs from CSB patient GM00739 (Andrade et al., 2012) were cultured in
mTeSR1media (Stem Cell Technologies) onMatrigel (Corning)-coated culture-
ware,withdailymediachanges.Neuraldifferentiationwasperformedaccording
to published methods (Brennand et al., 2011), with minor modifications. Cells
from iPSC colonies were harvested using Accutase (Sigma), and embryoid
bodies were formed by seeding single cells into Aggrewell 800 plates for 24 hr
in DMEM/F12 media supplemented with N2 supplement, non-essential amino
acids, 2 mg/ml heparin and penicillin/streptomycin (all from Life Technologies),
as well as 10 ng/ml fibroblast growth factor 2 and 2 mM dosomorphin (both
fromSigma), 10mMSB431542 (Stemgent), and10mMY-27632 (StemCell Tech-
nologies).Cellswereallowed to formembryoidbodies for 24hr inside theAggre-
wells, and then they were transferred to fresh media without 10 mM Y-27632 in
low-attachment six-well plates (Corning). Embryoid bodies were grown for
4 days, with daily media changes. Embryoid bodies were then transferred to
six-well plates coated with 0.1 mg/ml poly-L-ornithine (Sigma) and 20 mg/ml
laminin (Life Technologies) to form rosettes. Rosette media consisted of
DMEM/F12 media supplemented with N2 supplement, non-essential amino
acids, 2 mg/ml heparin, B27 supplement without vitamin A, penicillin/strepto-
mycin, 1 mg/ml laminin (all from Life Technologies), and 10 ng/ml fibroblast
growth factor 2 (Sigma). Rosettes were grown for 1 week, with media changes
every other day until the appearance of rosette structures. Rosettes were har-
vested manually and dissociated with Accutase (Sigma). The resultant neural
precursors were grown for two passages on six-well plates in neural precursor
media; this was identical to rosette media, except that the concentration of
fibroblast growth factor 2was increased to 20 ng/ml (Sigma). Neural precursors
were grown on six-well plates coated with 0.1 mg/ml poly-L-ornithine (Sigma)
and 10 mg/ml laminin (Life Technologies), with media changes every other day
and passages every 5 days. In order to induce neuronal differentiation, cells
were harvested with Accutase and grown in neuronal differentiation media.
Differentiation media consisted of neurobasal media supplemented with N2
supplement and B27 supplement lacking vitamin A, glutaMAX, penicillin/strep-
tomycin and 1 mg/ml laminin (all from Life Technologies), 1 mM dibutyryl cyclic
AMP and 200 ng/ml ascorbic acid (both from Sigma), 10 ng/ml BDNF,
10 ng/ml glial-cell-derived neurotrophic factor (GDNF) and 10 ng/ml insulin-
like growth factor 1 (IGF-1) (all from Peprotech). Cells were cultured in ibidi
m-Slide eight-well slides (ibidi USA). At the time of seeding, cells were cultured
in the presence of 50 nM amitriptyline, 50 nM 7,8-DHF or saline vehicle. Drug
treatments were performed in duplicate wells and on duplicate slides. Media
anddrugswerechangedeveryotherday,andafter 1weekofdrug treatment,cul-
tureswere fixedwith 4%paraformaldehyde. As a separate experiment, an addi-
tional vial of CSB iPSCs was processed through the full differentiation protocol
several weeks later to confirm reproducibility. Fixed cells were stained overnight
with antibodies against Tuj1 (1:1,000, Stem Cell Technologies) followed by goat
anti-mouse antibodies conjugated to Alexa Fluor 488 (1:1,000, Life Technolo-
gies) and mounting media containing DAPI (Vector Laboratories). Images were
obtained with an inverted fluorescence microscope (AxioVert, Zeiss) using
Velocity software (PerkinElmer), with the imaging analyst blinded to treatment
group. Neuronal morphology was quantified using MetaMorph software equip-
pedwith the neurite outgrowthmodule (MolecularDevices),with the imaging an-
alyst blinded to treatment group. 500–800 cells were analyzed per treatment
group. For statistical testing, neurite number and branching were analyzed
with a one-way ANOVA, followed by Bonferroni post hoc testing. Neurite length
was analyzed with the Kruskal-Wallis test, followed by Dunn’s post hoc test.
Statistical testing was performed with GraphPad Prism 5 software (GraphPad
Software). Differences were considered statistically significant at p < 0.05.
Transcriptome Analysis
Cerebrum samples fromCSpatients and age-matched controls were provided
by the NIH NeuroBioBank (NBB). The clinical history of patients was described2560 Cell Reports 14, 2554–2561, March 22, 2016 ª2016 The Authorpreviously (Wang et al., 2014)). Total RNA from 100 mg of frozen brain tissue
was isolated using the QIAGEN RNeasy Lipid Tissue Mini Kit. RNA concen-
tration and integrity (RIN) were assessed by Agilent Bioanalyzer Nano ChIP.
Double-stranded cDNA synthesis and DNA microarray was performed as
described earlier (see also Wang et al., 2014).
DNA Microarray Statistic Analysis
Data were analyzed using Bioconductor 2.12 (http://www.bioconductor.org)
running on R 3.0.0. Raw pair files (NimbleGen Homo sapiens HG18 expression
array) were quantile normalized in R. Differential gene expression was as-
sessed using an empirical Bayes t test (Limma package). The p values were
adjusted for multiple testing using the Benjamini-Hochberg method (Smyth,
2005). Any probe sets that exhibited an adjusted p value of 0.05 were defined
as differentially expressed. In addition, any probe sets that exhibited an abso-
lute fold change of >1.5 were used to generate a heatmap.
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